Why did PHASQ stock fall 99% today?

PHASQ stock fell 99.00% due to extremely thin liquidity, post-reorganization uncertainty, and lack of near-term commercial catalysts. Low average volume and investor de-risking around clinical and corporate outcomes amplified price moves.

What is Meyka AI's grade for PHASQ stock and what does it mean?

Meyka AI rates PHASQ with a score out of 100: 62.76 (Grade B, Suggestion: HOLD). The grade factors in benchmark and sector comparisons, financial growth, key metrics and analyst signals and is informational, not investment advice.

What price targets and forecast does Meyka AI give for PHASQ stock?

Meyka AI's forecast model projects a 12-month base-case of $0.000500, a bullish $0.030000 target and a bearish $0.000001 scenario. These are model-based projections and not guarantees.

US Stocks

PHASQ falls 99% to $0.000001 PNK US: Liquidity questions weigh on outlook

ByHuzaifa Zahoor February 20, 2026February 20, 2026

PHASQ stock plunged 99.00% to $0.000001 on the PNK exchange (United States) during market hours, making PhaseBio Pharmaceuticals a clear top loser today. Trading volume reached 2,500 shares versus a 50-day average volume of 22,310, highlighting extremely thin liquidity. Investors are reacting to the company’s post-reorganization status, scarce float and continued pipeline uncertainty. We examine why PhaseBio Pharmaceuticals, Inc. (PHASQ) is trading near the penny-floor, connect financial metrics to price action, and outline scenarios for recovery or further downside.